Why tyrosine kinase inhibitor resistance is common in advanced gastrointestinal stromal tumors

View/ Open
Published Version
https://doi.org/10.12688/f1000research.2-152.v1Metadata
Show full item recordCitation
Tomasetti, Cristian, George D Demetri, and Giovanni Parmigiani. 2013. “Why tyrosine kinase inhibitor resistance is common in advanced gastrointestinal stromal tumors.” F1000Research 2 (1): 152. doi:10.12688/f1000research.2-152.v1. http://dx.doi.org/10.12688/f1000research.2-152.v1.Abstract
Background: Most patients with advanced gastrointestinal stromal tumors (GIST) develop drug resistance to tyrosine kinase inhibitors (TKIs) within two years of starting therapy, whereas most chronic myeloid leukemia (CML) patients in chronic phase still exhibit disease control after a decade on therapy. This article aims to explain this divergence in long term outcomes. Methods and results: By combining clinical and experimental observations with mathematical formulas we estimate that, in advanced GIST, the genetic changes responsible for resistance are generally already present at disease detection. Conclusion: This result has relevant clinical implications by providing support for the exploration of combination therapies.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3892920/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:11879540
Collections
- FAS Scholarly Articles [17582]
- HMS Scholarly Articles [17730]
- SPH Scholarly Articles [6387]
Contact administrator regarding this item (to report mistakes or request changes)